Search the Newsreel

Moderna, Inc. (MRNA) Stock Price, News, Quote & History

This article provides a detailed overview of Moderna, Inc. (MRNA) stock, including its real-time price, historical data, key financial metrics, and recent performance. It also offers company information, analyst insights, and earnings trends, positioning it as a comprehensive resource for potential investors.

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

Moderna (MRNA) ended the recent trading session at $198.88, demonstrating a +2.08% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.51%. At the same time, the Dow added 0.93%, and the tech-heavy Nasdaq …

Moderna Stock Reached New 52-Week High: What's Happening?

Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has …

Bernstein reiterates Moderna stock rating on mRNA platform progress

Bernstein SocGen Group has reiterated a Market Perform rating and a $45.00 price target for Moderna Inc. (NASDAQ: MRNA) shares, despite the stock's significant surge over the past year. Analysts highlighted that Intismeran validates the broader mRNA therapeutics platform, with promising melanoma data expected. …

Moderna (MRNA) Stock Looks Overvalued Against Its Current Sales Base

Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals

Moderna, Inc. (MRNA) stock surged nearly 7% to a 52-week high of $194.82, displaying a strong bullish trend above all major moving averages. However, technical indicators like the daily RSI14 at 75.12 and price trading above the upper Bollinger Band suggest the stock is …

Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Analysts

Moderna, Inc. (NASDAQ:MRNA) has received a consensus "Hold" recommendation from analysts, with four suggesting a sell, thirteen a hold, and seven a buy. The average 12-month price target is significantly lower than its current share price, yet the company reported better-than-expected quarterly revenue and …

Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.

Moderna (MRNA) stock rose 7% due to investor anticipation of positive Phase 3 melanoma data for its personalized cancer vaccine, intismeran autogene, at the ESMO conference on October 24. CEO Stéphane Bancel also repositioned Moderna as an mRNA platform company, rather than solely a …

Moderna Stock Trends After Hours - Moderna (NASDAQ:MRNA), Merck & Co (NYSE:MRK)

Moderna (MRNA) shares are trending after hours following an announcement regarding its investigational mRNA-based individualized neoantigen therapy, intismeran autogene. The company will present three abstracts, including Phase 3 trial data evaluating intismeran with Merck & Co.'s (MRK) pembrolizumab, at the European Society for Medical …

Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak

Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains …

Moderna's View of the Global Pharma Industry

Chief executive Stéphane Bancel shares what's next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness. Video Transcript 0:00 spk_0 …

Moderna Inc (MRNA) extends 12-week surge to 129.0%

The biotechnology stock closed at $154.04, with shorter-term gains still positive and the weekly trend screen active.

Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company. Continue Reading

Moderna (MRNA) Tied To AI Drug Push As Bob Langer Takes New Advisory Role

Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role …

Moderna (MRNA) Stock Looks Very Expensive As Shares Surge Over 1 Year

Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company's sales profile rather than just recent momentum and headlines? The stock is up a …

Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis

Moderna Inc. (MRNA) saw its stock rise by 5.16% due to positive market reaction to strong Phase 3 oncology trial data for its personalized cancer therapy and regulatory clearances for updated COVID-19 vaccines. Despite this recent upward momentum and positive analyst upgrades, the company …

Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Moderna's stock (MRNA) has surged over 500% in 2026, significantly outperforming its rival BioNTech, primarily due to positive top-line results from its personalized cancer therapy, intismeran, in a melanoma trial. The market is now keenly awaiting detailed Phase 3 data on October 24 at …

UBS reiterates Moderna stock rating ahead of melanoma data

UBS has reiterated a Neutral rating on Moderna Inc. (NASDAQ: MRNA) with a $150.00 price target ahead of anticipated Phase III melanoma trial results. The stock has seen significant movement, trading at $180.30, up over 20% in the past week, and near its 52-week …

MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going

Shares of Moderna MRNA rose 12% yesterday, even climbing to a new 52-week high of $176.86. The rally came as investors digested the company's announcement that it will present detailed data from the phase III INTerpath-001 study on intismeran autogene, its personalized mRNA cancer …

Moderna, Inc. (MRNA) To Present Phase 3 Melanoma Data at ESMO; Investor Webcast Set

Moderna (MRNA) is scheduled to present late-breaking Phase 3 data for its intismeran autogene in resected stage IIB–IV melanoma at the ESMO 2026 conference. The company will also host an investor webcast on October 24th to discuss these results. The acceptance of three abstracts, …

Moderna (MRNA) Stock Trades Up, Here Is Why

Moderna (MRNA) Stock Trades Up, Here Is Why What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued …

Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week

Moderna (MRNA) shares surged to a three-year high in anticipation of upcoming pipeline updates, particularly at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum. The company is expected to present further Phase 3 trial data for its melanoma treatment candidate, intismeran …

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology. Continue Reading

Moderna stock hits 52-week high at 176.75 USD

Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology …

Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’

Moderna will present detailed Phase 3 results for its personalized cancer therapy, Intismeran, at the ESMO Congress on October 24, 2026. This therapy, developed with Merck, previously showed significant improvements in melanoma recurrence-free and distant metastasis-free survival when combined with Keytruda. Retail investors are …

AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market

Advanced Micro Devices is on pace for its first record high since June 30, and a $1 trillion market cap. Continue Reading

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna's shares surged 9% after its Phase 3 melanoma vaccine study earned a coveted Presidential Symposium slot at the European Society for Medical Oncology congress, scheduled for October 24. This scheduling is seen by the market as a strong signal of the data's significance, …

Moderna presents cancer therapy data at ESMO congress

Moderna Inc. (NASDAQ: MRNA) announced that three abstracts concerning its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, have been accepted for presentation at the European Society for Medical Oncology Congress 2026. The presentations will include data from a Phase 3 study for resected stage …

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT …

Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug

Cellular Intelligence is trying to build an AI model that can predict and eventually control how living cells behave, the same way AI models predict text or images, in hopes of making new medicines faster and cheaper to develop. The company took a step …

The first mRNA flu shot is now available. Here's who can get it

The first mRNA flu shot, mFLUSIVA by Moderna, is now available in the U.S. for individuals aged 50 and older. This vaccine uses the same mRNA technology as COVID-19 shots and was found to be about 27% more effective than standard flu shots in …

Dow Jones Futures: Can The Market Rally Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas

The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas. Continue Reading

Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?

Moderna (MRNA) has been back in the spotlight after its appearance at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran. Recent trading has been volatile for Moderna, with …